Forma Therapeutics, Inc.
Clinical trials sponsored by Forma Therapeutics, Inc., explained in plain language.
-
New drug targets genetic weakness in Hard-to-Treat blood cancers
Disease control CompletedThis study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis Phase 2 study tested an experimental drug called etavopivat in 53 people with thalassemia or sickle cell disease. The goal was to see if the pill could safely reduce the number of red blood cell transfusions needed and raise hemoglobin levels. Participants took 400 mg of eta…
Phase: PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC